A Study of ARRY-142886 in Patients With Advanced Cancer

Advanced Cancer Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00085787
• Other study ID #: ARRY-0401
• Status: Completed
• Phase: Phase 1
• Start date: June 2004
• Est. completion date: February 2007

Study information

• Verified date: October 2020
• Source: Array BioPharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-142886.

This study has 2 parts. In the first part, patients will receive increasing doses of study drug in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Approximately 25 patients from the US will be enrolled in Part 1 (Completed).

In the second part of the study, patients will receive the best dose of study drug, determined from the first part of the study, and will be followed to see what side effects the study drug causes and what effectiveness the study drug has, if any, in treating the cancer. Approximately 35 patients from the US will be enrolled in Part 2 (Completed).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: February 2007
• Est. primary completion date: February 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria (Part 2):

• Histopathologically or cytologically confirmed solid tumor that is refractory to standard therapies, or for which no standard therapies exist, or for which the Investigator feels no other active therapy is required for the duration of the study.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.

• Estimated life expectancy of greater than or equal to 3 months.

• Patient must have a tumor that is accessible for biopsy and must consent to paired tumor biopsies and normal skin biopsies being taken pre- and post-dose of study drug.

• Additional criteria exist.

Key Exclusion Criteria (Part 2):

• Uncontrolled or symptomatic brain metastases.

• Use of investigational drug or device within 30 days prior to first dose of study drug.

• Major surgery within 30 days prior to study start.

• Radiotherapy or chemotherapy within 21 days prior to study start (not including palliative radiotherapy at focal sites).

• Pregnancy or lactation.

• Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C.

• Additional criteria exist.

Related Conditions & MeSH terms

• Advanced Cancer
• Neoplasms

Intervention

Drug:
• ARRY-142886, MEK inhibitor; oral
Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule

Locations

Country	Name	City	State
United States	University of Colorado Cancer Center, Anschutz Cancer Center	Aurora	Colorado
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	Mayo Clinic Rochester	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Array Biopharma, now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms.		Part 1
Primary	Establish the maximum tolerated dose (MTD) of study drug.		Part 1
Primary	Assess the biological activity of the study drug in tumors in terms of inhibition of extracellular signal-regulated kinase (ERK) phosphorylation.		Part 2
Secondary	Characterize the pharmacokinetics (PK) of the study drug in terms of plasma concentrations.		Part 1 and Part 2
Secondary	Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers.		Part 1 and Part 2
Secondary	Assess the efficacy of the study drug in terms of tumor dimension assessment.		Part 1 and Part 2
Secondary	Confirm the safety of the study drug at the MTD as determined by adverse events, clinical laboratory tests, vital signs and electrocardiograms.		Part 2